Compare DNA & RPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DNA | RPC |
|---|---|---|
| Founded | 2008 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 835.7M | 869.8M |
| IPO Year | 2020 | 2021 |
| Metric | DNA | RPC |
|---|---|---|
| Price | $11.22 | $7.96 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 3 | 4 |
| Target Price | $7.00 | ★ $12.75 |
| AVG Volume (30 Days) | ★ 3.0M | 544.8K |
| Earning Date | 11-05-2026 | 11-12-2026 |
| Dividend Yield | N/A | ★ 2.00% |
| EPS Growth | ★ 46.49 | 6.25 |
| EPS | N/A | ★ 0.14 |
| Revenue | $170,155,000.00 | ★ $297,346,000.00 |
| Revenue This Year | N/A | $20.02 |
| Revenue Next Year | $13.37 | $16.79 |
| P/E Ratio | ★ N/A | $57.00 |
| Revenue Growth | N/A | ★ 0.30 |
| 52 Week Low | $5.37 | $6.79 |
| 52 Week High | $18.22 | $9.51 |
| Indicator | DNA | RPC |
|---|---|---|
| Relative Strength Index (RSI) | 56.80 | 51.04 |
| Support Level | $6.86 | $7.32 |
| Resistance Level | N/A | $8.02 |
| Average True Range (ATR) | 1.63 | 0.26 |
| MACD | 0.20 | 0.07 |
| Stochastic Oscillator | 35.01 | 75.51 |
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.
Ridgepost Capital Inc, formelrly P10 Inc is a player in the alternative asset management sector, specializing in multi-asset class private market solutions. It offers a range of investment solutions, including specialized funds, separate accounts, secondary investments, direct investments, and co-investments across various asset classes and geographies. These solutions cater to diverse investor needs within the private markets, aiming to deliver superior risk-adjusted returns. With a focus on middle and lower-middle markets, the company's portfolio includes Private Equity, Venture Capital, Impact Investing, and Private Credit. Its Revenue mainly comes from recurring management and advisory fees earned on committed capital, typically locked up for ten to fifteen years.